What is the recommended medication protocol for a patient with a history of ischemic stroke, considering individual risk factors and medical history, including conditions such as atrial fibrillation and impaired blood pressure control?

Stroke Protocol Medication

For patients with acute ischemic stroke, administer IV tissue plasminogen activator (tPA) 0.9 mg/kg (maximum 90 mg) within 3 hours of symptom onset after excluding intracranial hemorrhage, followed by aspirin 160-325 mg within 48 hours if thrombolysis is not given; for secondary prevention, use dual antiplatelet therapy (aspirin plus clopidogrel) for 21-30 days in minor stroke/high-risk TIA, oral anticoagulation with direct oral anticoagulants for atrial fibrillation, high-dose statin therapy, and blood pressure control targeting systolic <140 mmHg. 1, 2, 3

Acute Phase Management (Time-Critical)

Thrombolytic Therapy

• IV tPA should be administered at 0.9 mg/kg (maximum 90 mg) over 1 hour if treatment can be initiated within 3 hours of clearly defined symptom onset (Grade 1A evidence). 4, 3, 5
• Target door-to-needle time ≤60 minutes. 3
• Between 3-4.5 hours, IV tPA may be considered but evidence is weaker (Grade 2C). 3, 5
• Do not use IV tPA beyond 4.5 hours from symptom onset (Grade 1A). 5
• Before tPA administration, blood pressure must be lowered to systolic <185 mmHg and diastolic <110 mmHg. 3
• Antiplatelet agents and anticoagulants are contraindicated for 24 hours after IV tPA administration. 4, 3

Immediate Antiplatelet Therapy (If Thrombolysis Not Given)

• Aspirin 160-325 mg should be administered within 48 hours of symptom onset after excluding intracranial hemorrhage on neuroimaging (Grade 1A). 1, 4, 2, 3, 5
• For patients with impaired swallowing, use rectal aspirin 325 mg daily or enteral tube administration of aspirin 81 mg or clopidogrel 75 mg daily. 1

Secondary Prevention Based on Stroke Etiology

Minor Stroke or High-Risk TIA (NIHSS ≤3 or ABCD2 ≥4)

Dual antiplatelet therapy is mandatory for these high-risk patients:

• Loading doses: Aspirin 160-325 mg plus clopidogrel 300-600 mg within 12-24 hours of symptom onset after excluding intracranial hemorrhage. 1, 2
• Maintenance: Aspirin 81 mg daily plus clopidogrel 75 mg daily for 21 days, then transition to single antiplatelet therapy. 1, 2
• Alternative regimen: Aspirin 75-100 mg plus ticagrelor 90 mg twice daily (loading doses: aspirin 300-325 mg, ticagrelor 180 mg) for 30 days. 1
• This dual therapy reduces recurrent ischemic stroke by 25-32% compared to monotherapy (Grade 1A evidence). 2

Non-Cardioembolic Stroke (Atherothrombotic, Lacunar, Cryptogenic)

Long-term single antiplatelet therapy is indicated:

• Preferred options: Clopidogrel 75 mg daily (Grade 2B) or aspirin 25 mg/extended-release dipyridamole 200 mg twice daily (Grade 1A) over aspirin alone. 1, 5, 6
• Aspirin 81-325 mg daily is acceptable but less preferred. 1
• Avoid long-term combination of aspirin plus clopidogrel (Grade 1B) due to increased bleeding risk without additional benefit. 5

Atrial Fibrillation (Cardioembolic Stroke)

Oral anticoagulation is mandatory:

• Direct oral anticoagulants (DOACs) are preferred over warfarin (Grade 2B). 1, 3
• Apixaban 5 mg twice daily (or 2.5 mg twice daily if ≥2 of: age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL) demonstrated superiority over warfarin with 21% relative risk reduction in stroke/systemic embolism. 7
• Initiate anticoagulation within 1-2 weeks after stroke onset; earlier initiation (within days) for small infarcts without hemorrhage on imaging. 3
• For valvular atrial fibrillation (mechanical valve or moderate-severe mitral stenosis), warfarin targeting INR 2.5 (range 2.0-3.0) is required. 1, 8
• Patients on anticoagulation should not receive antiplatelet therapy for secondary stroke prevention. 1

Intracranial Atherosclerotic Stenosis (50-99%)

• Dual antiplatelet therapy (aspirin plus clopidogrel) is recommended as appropriate medical therapy. 1
• High-dose statin therapy is mandatory. 1
• Blood pressure target: systolic <140 mmHg. 1
• At least moderate physical activity is recommended. 1

Risk Factor Management

Lipid Management

• High-dose statin therapy: Atorvastatin 80 mg daily for patients with LDL-cholesterol >2.5 mmol/L (>100 mg/dL). 1
• Target LDL-cholesterol <1.8 mmol/L (70 mg/dL) for all ischemic stroke/TIA patients. 1
• For atherosclerotic disease, target LDL <1.8 mmol/L; add ezetimibe if needed. 1
• Monitor lipid levels 1-3 months after initiation, then every 3-12 months. 1

Blood Pressure Control

• Systolic blood pressure target <140 mmHg for patients with intracranial atherosclerotic stenosis. 1
• Aggressive blood pressure control is recommended for all stroke patients in secondary prevention. 3

Venous Thromboembolism Prophylaxis

• Prophylactic-dose low-molecular-weight heparin is preferred over unfractionated heparin for immobilized patients (Grade 2B). 3, 5, 6
• Intermittent pneumatic compression devices are an alternative (Grade 2B). 3
• Avoid elastic compression stockings (Grade 2B). 3

Critical Safety Considerations

Bleeding Risk Assessment

• Always exclude intracranial hemorrhage on CT or MRI before administering any antiplatelet loading dose or anticoagulation. 1, 2
• Do not use loading doses in patients with active bleeding, high bleeding risk, severe thrombocytopenia, recent major surgery/trauma, or uncontrolled hypertension. 2

Special Populations

• Embolic stroke of undetermined source (ESUS): Use antiplatelet therapy, not oral anticoagulants. 1
• Extracranial artery dissection: Either antiplatelet therapy or oral anticoagulation for at least 3 months. 1
• Carotid web: Antiplatelet therapy is recommended. 1

Common Pitfalls to Avoid

• Do not delay tPA administration for minor symptoms—time is brain, and the 3-hour window is critical. 3, 5
• Do not use urgent anticoagulation to prevent early recurrent stroke or halt neurological worsening—this is not recommended and increases hemorrhage risk (Grade III). 4
• Do not continue dual antiplatelet therapy beyond 21-30 days in minor stroke/TIA—transition to single agent to reduce bleeding risk. 1, 2
• Do not use antiplatelet therapy in patients who require anticoagulation for atrial fibrillation—anticoagulation alone is sufficient and safer. 1
• Do not use streptokinase for acute ischemic stroke (Grade 1A). 6